Sustained pricing pressure in generics
Pricing pressure and competitive intensity continue to impact the US and API businesses, potentially limiting margin expansion.
high · management_commentary
Alembic Pharmaceuticals Limited — Q4 FY26
Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25% (vs 24% YoY).
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US branded business margin drag
The launch of Pivya and the US branded specialty business will drag margins by 100-150 bps in the near term, with uncertain timing of breakeven.
medium · management_commentaryR&D productivity and elevated spend
R&D spend increased to 11% of revenue in Q4, and guidance for FY27 is elevated at ₹750-800 crore; returns on this investment are uncertain.
medium · analyst_questionNew facility ramp-up delays
F2 and F3 facilities are still underutilized (40-60% on some lines), and revenue contribution from contract manufacturing may take time to materialize.
medium · analyst_question